

# TABLE OF CONTENTS

March 15, 2010

No. 2180

## BUSINESS

- 1 Merger with Schering-Plough to Make Merck 8th Company in Japan
  - Merck to Enhance R&D in CV, Infectious Diseases
  - Complementary Effects Expected for Hepatitis C, Cancer
- 2 Shionogi Licenses Ospemifene from QuatRx
- 3 Astellas to Enhance Oncology Pipeline through TOB of OSI
  - Astellas Files Lawsuit against OSI
- 3 Pfizer Japan: Sales Up 2.6% despite Fall in Sales of Norvasc
- 4 Toyobo's Sales to Top ¥400 Bil. in FY2015 Driven by Life Science Business
- 4 EFPIA Japan to Work to Eliminate Drug Lag
- 5 Teijin Licenses SB623 from SanBio
- 5 2009 Sales of Ethical Drugs Up 7.2% to ¥8,851.6 Bil.: IMS Japan
  - Blopress Ranked No. 1, Diovan No. 2
- 6 **BUSINESS NEWS IN BRIEF**
  - Banyu, Santen to Copromote Cosopt
  - Kyowa Kirin, Solasia Sign License Agreement for Sancuso in Asia
  - NanoCarrier to Obtain Process Patent on NC-4016 in the US
  - Tsumura to Procure Raw Materials for *Kampo* Medicines in Laos
  - Quintiles Starts Tissue Testing Services in China
  - Suzuken Ties Up with Frontier for Dispensing Pharmacy Business
  - CareNet Obtains Patent on e-Detailing Service

## MEDICAL DEVICES

- 7 Mr Matsumura of Terumo Calls For Regulatory Reform of Medical Devices

## REGULATORY

- 8 New NHI Prices Applicable from April 1 Announced
  - New Premium Granted to 624 Products, 337 APIs
  - Astellas the Only Domestic Company Among Top-10 Premium Beneficiaries
  - Average of 8.5% Price Cut for Long-Listed Original Products
  - 16 Products, 7 APIs Granted New Premium for Value Added after Launching
  - NHI Prices Raised for 38 Products, 20 APIs for Non-Profitability

- 11 Price Reduction Rate Lowest for Eli Lilly, Highest for Chemiphar
- 12 Two-Digit Price Cuts for 27 Products from 35 Leading Companies
  - 7-8% Down for ARBs
  - Loss Greater Than Benefit for 60% of Companies
  - Burden of Development Greater than Premium's Benefit for 45% of Companies
- 13 Premium Will Be Effective for Expediting Development of New Drugs, Indications: Mr Nagatsuma
- 17 *Koroshō* Starts Hearing Major Chain Pharmacy Operators
- 17 **REGULATORY NEWS IN BRIEF**
  - Astellas Withdraws Application for Diabetic Incipient Nephropathy for Micardis
  - *Koroshō* to Prepare for 2nd Round of Screening by GRU
  - Sanofi-aventis Begins Post-marketing Program on Apidra

## R&D

- 18 Takeda to Initiate PIII Trials for Lu AA21004, Lu AA24530 in the US
- 19 Eli Lilly, Merck, Pfizer to Jointly Create Cancer DB in Asia
- 19 **R&D NEWS IN BRIEF**
  - SymBio Begins PII Trial of Bendamustine for Aggressive NHL
  - JCPM to Provide e-Learning Programs for Clinical Trials

## SELF-MEDICATION

- 20 Ms Shiono to Be Promoted to President of SSP
- 20 Switch OTC Drugs Market Up 2.3% to ¥157.1 Bil. in 2009: Fuji-Keizai

## GENERICS

- 21 Deepest Price Cuts for Lanbaxy/I'rom's Amlodipine Generics
- 21 Sawai to Boost Sales to ¥74 Bil. by March 2012
- 22 12 Generics Priced Higher Than Their Originals

## MEDICAL FACILITIES & NURSING CARE

- 22 Don't Create Any More New Medical Schools: AJMC
- 23 3 Candidates for JMA President Election
- 23 Group Organized to Increase Awareness of COPD